inVentiv buys Star Terre Santé for French pharma comms

Related tags Subsidiary Merck serono

inVentiv Health has acquired Star Terre Santé to expand its healthcare communications footprint into France.

Acquiring Star Terre Santé, also know as Substrat'Homme SA, gives inVentiv Communications a presence in France. Using this base inVentiv will serve clients in France and neighbouring Belgium, Luxembourg and the Netherlands.

We are thrilled to formalise our relationship with them and we look forward to continuing to work together to serve our growing base of clients that are marketing products in Europe​", said Phil Deschamps, chief global officer of inVentiv Communications.

The inVentiv Communications’ network now has a presence in 16 markets. Furthermore, Chandler Chicco Companies, a part of inVentiv Communications, has a presence in 37 countries.

Star Terre Santé is comprised of seven healthcare-focused communications units and lists Merck Serono, Eli Lilly and Johnson & Johnson among its clients.

For Star Terre Santé joining the inVentiv network gives it access to experience and a broad range of resources. Stéphane Laford, president of Star Terre Santé, said these were characteristics the company was looking for when considering partnering to expand.

inVentiv's unique focus in healthcare and their breadth of service offerings for pharmaceutical and biotech clients makes them an ideal partner for us​", said Laford.

Star Terre Santé and inVentiv have partnered since 2009 to meet the marketing and advertising needs of France-based clients. Formalising this relationship through acquisition makes Star Terre Santé a wholly owned subsidiary of inVentiv.

Financial details of the deal were not disclosed.

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...